Afif Nakhleh1, Naim Shehadeh2, Irit Hochberg2, Moshe Zloczower2, Sagit Zolotov2, Riad Taher2, Deeb Daoud Naccache2. 1. Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, HaAliya HaShniya Street 8, 3109601, Haifa, Israel. anakhleh@gmail.com. 2. Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, HaAliya HaShniya Street 8, 3109601, Haifa, Israel.
Abstract
INTRODUCTION: Cystic prolactinoma is a variant of prolactin-secreting pituitary adenoma. The strategies for the management of cystic prolactinoma have not been addressed thoroughly in clinical guidelines. METHODS: A literature search was performed using Pubmed to review the current approaches to the treatment of cystic prolactinoma. RESULTS: Transsphenoidal resection is an effective and relatively safe approach for the treatment of cystic prolactinoma, however, morbidity of surgery is dependent on the skill of the surgeon. Emerging studies allude to the efficacy and safety of dopamine agonists in the management of cystic prolactinoma. Dopamine agonists are associated with considerable rates of clinical improvement and tumor shrinkage, hence reducing the need for surgical intervention. CONCLUSIONS: Recent studies suggest that dopamine agonist therapy may be an effective and safe treatment option in a considerable portion of patients with cystic prolactinomas. We suggest that dopamine agonists should be considered as a first-line therapy for cystic prolactinoma in the absence of indications for early surgical intervention.
INTRODUCTION:Cystic prolactinoma is a variant of prolactin-secreting pituitary adenoma. The strategies for the management of cystic prolactinoma have not been addressed thoroughly in clinical guidelines. METHODS: A literature search was performed using Pubmed to review the current approaches to the treatment of cystic prolactinoma. RESULTS: Transsphenoidal resection is an effective and relatively safe approach for the treatment of cystic prolactinoma, however, morbidity of surgery is dependent on the skill of the surgeon. Emerging studies allude to the efficacy and safety of dopamine agonists in the management of cystic prolactinoma. Dopamine agonists are associated with considerable rates of clinical improvement and tumor shrinkage, hence reducing the need for surgical intervention. CONCLUSIONS: Recent studies suggest that dopamine agonist therapy may be an effective and safe treatment option in a considerable portion of patients with cystic prolactinomas. We suggest that dopamine agonists should be considered as a first-line therapy for cystic prolactinoma in the absence of indications for early surgical intervention.
Entities:
Keywords:
Apoplexy; Cystic prolactinoma; Dopamine agonist; Transsphenoidal surgery
Authors: Felipe F Casanueva; Mark E Molitch; Janet A Schlechte; Roger Abs; Vivien Bonert; Marcello D Bronstein; Thierry Brue; Paolo Cappabianca; Annamaria Colao; Rudolf Fahlbusch; Hugo Fideleff; Moshe Hadani; Paul Kelly; David Kleinberg; Edward Laws; Josef Marek; Maurice Scanlon; Luis G Sobrinho; John A H Wass; Andrea Giustina Journal: Clin Endocrinol (Oxf) Date: 2006-08 Impact factor: 3.478
Authors: Niki Karavitaki; Gaya Thanabalasingham; Helena C A Shore; Raluca Trifanescu; Olaf Ansorge; Niki Meston; Helen E Turner; John A H Wass Journal: Clin Endocrinol (Oxf) Date: 2006-10 Impact factor: 3.478
Authors: J Kreutzer; R Buslei; H Wallaschofski; B Hofmann; C Nimsky; R Fahlbusch; M Buchfelder Journal: Eur J Endocrinol Date: 2008-01 Impact factor: 6.664
Authors: Biji Bahuleyan; Girish Menon; Suresh Nair; B R M Rao; H V Easwer; Kumar Krishna Journal: J Clin Neurosci Date: 2009-08-20 Impact factor: 1.961
Authors: Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana Journal: Eur J Endocrinol Date: 2022-02-03 Impact factor: 6.664